Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
CatalYm GmbH
Replimune Inc.
Boehringer Ingelheim
University Medical Center Groningen
Bristol-Myers Squibb
Bristol-Myers Squibb
PrECOG, LLC.
Sanofi
Inimmune Corporation
BicycleTx Limited
University of Kansas Medical Center
Bristol-Myers Squibb
Vivace Therapeutics, Inc
University Hospital, Lille
7 Hills Pharma, LLC
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
TCR2 Therapeutics
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
Exelixis
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
University of Southampton
Universitair Ziekenhuis Brussel
Bristol-Myers Squibb
Molecular Templates, Inc.
Bristol-Myers Squibb
Hoosier Cancer Research Network
Mirati Therapeutics Inc.
Ono Pharmaceutical Co. Ltd
Oslo University Hospital
Canadian Cancer Trials Group
Centre Hospitalier Universitaire Vaudois
Bristol-Myers Squibb
University of Chicago
Ono Pharmaceutical Co. Ltd
M.D. Anderson Cancer Center
Jules Bordet Institute
Bristol-Myers Squibb
Bristol-Myers Squibb
Incyte Corporation
Momotaro-Gene Inc.
Infinity Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.